Mr. Stefano Picone reports

CONAVI MEDICAL ANNOUNCES NEW GRANT OF STOCK OPTIONS

Conavi Medical Corp.'s board of directors approved grants of stock options on June 2, 2025, pursuant to the terms of the company's omnibus equity incentive plan. A total of 5,849,098 stock options have been awarded to directors, officers, employees and consultants of the company. The stock options are exercisable at a price of 39 cents per share (being the closing price of the company's shares on the TSX Venture Exchange on June 2, 2025) for a period of 10 years from the date of grant.

A total of 1,930,172 of such stock options were allocated as follows to the company's independent directors: 341,624 stock options to Anthony Giovinazzo, 341,624 stock options to Cathy Steiner, 330,807 stock options to Robert Mitchell, 358,242 stock options to Susan Allen and 557,875 stock options to Aaron Davidson.

A total of 3,581,216 of such stock options were allocated as follows to the company's officers: 298,413 stock options to Travis More, 266,863 stock options to Amandeep Thind, 393,924 stock options to Sumeet Dham, 425,000 stock options to Stefano Picone and 2,197,646 stock options to Thomas Looby.

The remaining stock options were granted to other employees and consultants.

The company has made minor changes to the composition of its audit committee, with board chair Mr. Davidson having stepped down from the audit committee and independent directors Ms. Allen, Ms. Steiner and Mr. Mitchell continuing to serve.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the United States Food and Drug Administration, and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

We seek Safe Harbor.